Participant flow

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment · Source last updated 2015-10-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   The dose of sunitinib malate will be a continuous daily dose of 37.5 mg administered orally for 6 weeks. The cycle of therapy is 42 days (or 6 weeks) sunitinib malate

   id

   FG000

   title

   Sunitinib Malate

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         10

      type

      Progression of Disease

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         10

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice